Hepatitis C and HIV incidence and harm reduction program use in a conflict setting: An observational cohort of injecting drug users in Kabul, Afghanistan

Harm Reduction Journal

Volumn 12, Issue 1, 2015, Pages

  Todd, Catherine S ^a,f   Nasir, Abdul ^b   Stanekzai, Mohammad Raza ^b   Fiekert, Katja ^b   Sipsma, Heather L ^c   Vlahov, David ^d   Strathdee, Steffanie A ^e  

^a Department of Medicine   (United States)

^b Health Protection and Research Organisation   (Afghanistan)

^c YALE UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f FAMILY HEALTH INTERNATIONAL   (United States)

Author keywords

Afghanistan; Armed conflict; Harm reduction; Hepatitis C virus; HIV; Injecting drug use

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ADULT; AFGHANISTAN; ARTICLE; COHORT ANALYSIS; DISEASE TRANSMISSION; ENVIRONMENTAL FACTOR; FOLLOW UP; HARM REDUCTION; HEALTH PROGRAM; HEALTH SERVICE; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOASSAY; INCIDENCE; INTRAVENOUS DRUG ABUSE; MALE; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; RISK FACTOR; SEXUAL BEHAVIOR; SMOKING HABIT; COMORBIDITY; DRUG USE; HIV INFECTIONS; NEEDLE SHARING; PREVENTIVE HEALTH SERVICE; STATISTICS AND NUMERICAL DATA; SUBSTANCE ABUSE; WAR;

ADULT; AFGHAN CAMPAIGN 2001-; AFGHANISTAN; COHORT STUDIES; COMORBIDITY; DRUG USERS; HARM REDUCTION; HEPATITIS C; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; NEEDLE SHARING; NEEDLE-EXCHANGE PROGRAMS; RISK FACTORS; RISK-TAKING; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84944893410     PISSN: None     EISSN: 14777517     Source Type: Journal    
DOI: 10.1186/s12954-015-0056-z     Document Type: Article

References (41)

1. Mock NB, Duale S, Brown LF, Mathys E, O'Maonaigh HC, Abul-Husn NK, et al. Conflict and HIV: a framework for risk assessment to prevent HIV in conflict-affected settings in Africa. Emerg Themes Epidemiol. 2004;1:6.
2. Mills EJ, Singh S, Nelson BD, Nachega JB. The impact of conflict on HIV/AIDS in sub-Saharan Africa. Int J STD AIDS. 2006;17:713-7.
3. Spiegel PB, Bennedsen AR, Claass J, Bruns L, Patterson N, Yiweza D, et al. Prevalence of HIV infection in conflict-affected and displaced people in seven sub-Saharan African countries: a systematic review. Lancet. 2007;369:2187-95.
4. Anema A, Joffres MR, Mills E, Spiegel PB. Widespread rape does not directly appear to increase the overall HIV prevalence in conflict-affected countries: so now what? Emerg Themes Epidemiol. 2008;5:11.
5. Kim AA, Malele F, Kaiser R, Mama N, Kinkela T, Mantshumba JC, et al. HIV infection among internally displaced women and women residing in river populations along the Congo River, Democratic Republic of Congo. AIDS Behav. 2009;13:914-20.
6. Ezard N, Oppenheimer E, Burton A, Schilperoord M, Macdonald D, Adelekan M, et al. Six rapid assessments of alcohol and other substance use in populations displaced by conflict. Confl Health. 2011;5:1.
7. Carballo M, Puvacic S, Zeric D. Implications of complex emergencies, uprooting and forced migration on risk of HIV/AIDS: the case of Bosnia and Herzegovina. Abstract 244/14139. Geneva: XII World AIDS Conference; 2002.
8. Strathdee SA, Stachowiak JA, Todd CS, Al-Delaimy WK, Wiebel W, Hankins C, et al. Complex emergencies, HIV, and substance use: no "big easy" solution. Subst Use Misuse. 2006;41:1637-51.
9. United Nations Office on Drugs and Crime (UNODC). Drug use in Afghanistan: 2009 survey. Executive summary. Kabul, Afghanistan: UNODC; 2010.
10. United Nations Office for the Coordination of Humanitarian Affairs (UN OCHA). Humanitarian update-Afghanistan-December 2010. Kabul, Afghanistan: UN OCHA; 2011.
11. Rubin BR. Road to ruin: Afghanistan's booming opium industry. Center for American Progress & Center on International Cooperation: New York, USA; 2004.
12. Chivers CJ. In Eastern Afghanistan, at war with the Taliban's shadowy rule. The New York Times, February 6, 2011. http://www.nytimes.com/2011/02/07/world/asia/07taliban.html?pagewanted=all. Accessed 26 Feb 2015.
13. World Bank/ United National High Commissioner for Refugees (UNHCR). Research study on IDPs in urban settings-Afghanistan. Kabul: World Bank/UNHCR; 2011.
14. Todd CS, MacDonald D, Khoshnood K, Mansoor GF, Eggerman M, Panter-Brick C. Opiate use, treatment, and harm reduction in Afghanistan: recent changes and future directions. Int J Dru Pol. 2012;23:341-5.
15. Todd CS, Abed A, Strathdee SA, Scott PT, Botros BA, Safi N, et al. Prevalence of HIV, hepatitis C, hepatitis B, and associated risk behaviors among injection drug users in Kabul, Afghanistan. Emerg Infect Dis. 2007;13:1327-31.
16. Nasir A, Todd CS, Stanekzai MR, Bautista CT, Botros BA, Scott PT, et al. Prevalence of HIV, hepatitis B and hepatitis C and associated risk behaviours amongst injecting drug users in three Afghan cities. Int J Drug Policy. 2011;22:145-52.
17. Ruiseñor-Escudero H, Wirtz AL, Berry M, Mfochive-Njindan I, Paikan F, Yousufi HA, et al. Risky behavior and correlates of HIV and hepatitis C virus infection among people who inject drugs in three cities in Afghanistan. Drug Alcohol Depend. 2014;143:127-33.
18. Beyrer C, Wirtz AL, Baral S, Peryskina A, Sifakis F. Epidemiologic links between drug use and HIV epidemics: an international perspective. J Acquir Imm Def Synd. 2010;55(S1):S10-6.
19. Griffin N, Khoshnood K. Opium trade, insurgency, and HIV/AIDS in Afghanistan: relationships and regional consequences. Asia Pac J Public Health. 2010;22:159S-67S.
20. Rehman S, Rasoul MZ, Wodak A, Claeson M, Friedman J, Sayed GD. Responding to HIV in Afghanistan. Lancet. 2007;370:2167-9.
21. Maguet O, Majeed M. Implementing harm reduction for heroin users in Afghanistan, the worldwide opium supplier. Int J Drug Policy. 2010;21:119-21.
22. World Bank South Asia Region Human Development Sector. Mapping and situation assessment of key populations at high risk of HIV in three cities of Afghanistan. World Bank: Washington D.C.; 2008.
23. The Afghanistan NGO Safety Office (ANSO). ANSO quarterly data report Q4. 2009. Kabul, Afghanistan: ANSO; 2010.
24. Todd CS, Nasir A, Stanekzai MR, Fiekert K, Rasuli MZ, Vlahov D, et al. Prevalence and correlates of HIV, syphilis, and hepatitis B and C infection and harm reduction program use among male injecting drug users in Kabul, Afghanistan: a cross-sectional assessment. Harm Reduct J. 2011;8:22.
25. Todd CS, Stibich MA, Stanekzai MR, Rasuli MZ, Bayan S, Wardak SR, et al. A qualitative assessment of injection drug use and harm reduction programmes in Kabul, Afghanistan: 2006-2007. Int J Drug Policy. 2009;20:111-20.
26. Ezard N. Substance use among populations displaced by conflict: a literature review. Disasters. 2012;36:533-57.
27. Rhodes T, Singer M, Bourgois P, Friedman SR, Strathdee SA. The social structural production of HIV risk among injecting drug users. Soc Sci Med. 2005;61:1026-44.
28. Friedman SR, Rossi D, Braine N. Theorizing "Big Events" as a potential risk environment for drug use, drug-related harm and HIV epidemic outbreaks. Int J Drug Policy. 2009;20:283-91.
29. Hankins CA, Friedman SR, Zafar T, Strathdee SA. Transmission and prevention of HIV and sexually transmitted infections in war settings: implications for current and future armed conflicts. AIDS. 2002;16:2245-52.
30. Blomé MA, Björkman P, Flamholc L, Jacobsson H, Molnegren V, Widell A. Minimal transmission of HIV despite persistently high transmission of hepatitis C virus in a Swedish needle exchange program. J Viral Hepat. 2011;18:831-9.
31. Fuller CM, Ompad DC, Galea S, Wu Y, Koblin B, Vlahov D. Hepatitis C incidence-a comparison between injection and noninjection drug users in New York City. J Urban Health. 2004;81:20-4.
32. Des Jarlais DC, Diaz T, Perlis T, Vlahov D, Maslow C, Latka M, et al. Variability in the incidence of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection among young injecting drug users in New York City. Am J Epidemiol. 2003;157:467-71.
33. Patrick DM, Tyndall MW, Cornelisse PG, Li K, Sherlock CH, Rekart ML, et al. Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection. CMAJ. 2001;165:889-95.
34. Ruan Y, Qin G, Yin L, Chen K, Qian HZ, Hao C, et al. Incidence of HIV, hepatitis C and hepatitis B viruses among injection drug users in southwestern China: a 3-year follow-up study. AIDS. 2007;21S:S39-46.
35. Wand H, Spiegelman D, Law M, Jalaludin B, Kaldor J, Maher L. Estimating population attributable risk for hepatitis C seroconversion in injecting drug users in Australia: implications for prevention policy and planning. Addiction. 2009;104:2049-56.
36. Emmanuel F, Archibald C, Razaque A, Sandstrom P. Factors associated with an explosive HIV epidemic among injecting drug users in Sargodha. Pakistan J Acquir Immune Defic Syndr. 2009;51:85-90.
37. World Health Organization (WHO). Guidance on prevention of viral hepatitis B and C among people who inject drugs. Geneva: WHO; 2012.
38. WHO/Joint United Nations Programme on HIV/AIDS (UNAIDS), UNODC. Technical guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users, 2012 revision. Geneva: WHO; 2012.
39. Wodak A, Cooney A. Do needle syringe programs reduce HIV infection among injecting drug users: a comprehensive review of the international evidence. Subst Use Misuse. 2006;41:777-813.
40. Hagan H. Hepatitis C virus transmission dynamics in injection drug users. Substance Use & Misuse. 1998;33:1197-212.
41. Afghan Public Health Institute, Ministry of Public Health (APHI/MoPH), Central Statistics Organization (CSO), ICF Macro, Indian Institute of Health Management Research (IIHMR), World Health Organization Regional Office for the Eastern Mediterranean (WHO/EMRO). Afghanistan mortality Survey 2010. Calverton, Maryland, USA: APHI/MoPH, CSO, ICF Macro, IIHMR and WHO/EMRO; 2011.